

STATUS OF THE STRUCTURAL BIOLOGY AT THE PHOTON FACTORY



STATUS OF THE STRUCTURAL BIOLOGY AT THE PHOTON FACTORY

Soichi Wakatsuki

Ryuichi Kato

Noriyuki Igarashi

Masato Kawasaki

Nobutaka Shimizu

Masahiko Hiraki

Naohiro Matsugaki

Yusuke Yamada

Leonard Chavas

Tomoko Zeniya

Rieko Sukegawa

Gin Ishikawa

Ritsuko Ebisawa

Kentaro Ihara

Norio Kudo

Hisayoshi Makio

Seiji Okazaki

Hironori Suzuki

Tamami Uejima

Simon Miller

Kensuke Nakamura

Tetsuya Sakurai

Tamie Aoki

Kumiko Sasajima

Shokei Watanabe

Kazutaka Demura

Tomoya Oota

Takayuki Kubota

Shinji Naito

Rei Tanabe

Kenichi Kawasaki


Kotaro Kuroya



OUTLINE

- **Where are we?**
- **What are we doing?**
 - ~ introduction on structural biology
 - ~ R&D : application to structural biology
 - ~ synchrotron science
 - ... AR-NE3A: high-throughput beamline
 - ... BL-IA: low energy beamline
- **Structural biology applied to influenza virus and human neuraminidases: involvement R&D and synchrotron science**
- **New applications**
 - ~ R & D : UV-based centering and phasing
 - ~ synchrotron science : high-pressure studies
- **Conclusions**
- **Acknowledgments**

PHOTON FACTORY - SBRC



NE3A

**Structural Biology
Research Center**

**PF AR
6.5 GeV**

LINAC

BL-17A

**PF
2.5 GeV**

NW12A


BL-1A

BL-5A

• **Where are we?**




@DESY - 2012

RESEARCH AND SUPPORT ACTIVITIES



• What are we doing?


RESEARCH AND SUPPORT ACTIVITIES



**STRUCTURAL &
FUNCTIONAL BIOLOGY**



R&D



SYNCHROTRON SCIENCE




• What are we doing?

STRUCTURAL BIOLOGY

The collage illustrates the interdisciplinary nature of structural biology. At the top, a bar chart shows a progression from a 'Target' to a final stage marked with a '\$' symbol. Below this, a DNA double helix and a complex protein structure are shown. A virus is depicted on the left, and a person is shown in the center. A Nobel Prize medal and a Roche pill blister pack are at the bottom right. Various scientific and technological icons, including a microscope, a petri dish, a syringe, a lightbulb, a penguin, and a cloud icon, are scattered throughout the image.



structural biology

@DESY - 2012

[illegible][illegible][illegible][illegible]

STRUCTURAL BIOLOGY

Identify a
target model



structural biology

BIOLOGICAL MODEL: INFLUENZA

Oxford American Dictionaries:

“...a highly contagious viral infection of the respiratory passages causing fever, severe aching, and catarrh, and often occurring in epidemics...”




abnormal blue comb



swelling of the wattles



congestion of hocks and shanks



“Avian (or bird) flu is caused by influenza viruses that occur naturally among wild birds. The H5N1 variant is deadly to domestic fowl and can be transmitted from birds to humans. There is no human immunity and no vaccine is available.”

As of 2010:

- 508 human cases
- 302 deaths

BIOLOGICAL MODEL: INFLUENZA

H5N1

As of 2010:


- 508 human cases
- 302 deaths



H1N1

As of 2010:

- ~ 61 million human cases
- ~ 12 470 deaths



“H1N1 is a new influenza A virus that has never before circulated among humans. This virus is not related to previous or current human seasonal influenza viruses.”

STRUCTURAL BIOLOGY

Identify a
target model

Detailed
analysis




Target

\$

~ structural biology

@DESY - 2012


RESEARCH AND SUPPORT ACTIVITIES




**STRUCTURAL &
FUNCTIONAL BIOLOGY**




R&D



SYNCHROTRON SCIENCE




INFLUENZA VIRUS PROTEINS



Haemagglutinin (HA)



Neuraminidase (NA)




Influenza virus is an RNA type virus

Haemagglutinin (HA) & Neuraminidase (NA) are 2 surface proteins that help to parasite the host cell


- **HA recognizes sialic acid receptors at the plasma membrane; necessary for the virus entrance**
- **NA hydrolyzes the sialic acid of the receptor; necessary for newly formed virion's release and virus propagation**



ANTI-VIRAL DRUGS FOR FLU TREATMENT




sialic acid



DANA



**zanamivir
(Relenza)**




**oseltamivir
(Tamiflu)**

... influenza virus

ANTI-VIRAL DRUGS FOR FLU TREATMENT

Recognition specificity:


- **carboxyl head group**
- **guanidinium group**
- **lipophilic group**



HUMAN NAs

- **Neu1**

- lysosomal membrane sialidase
- mutations associated with lysosomal storage diseases (sialidosis; galactosialidosis)




- **Neu2**

- cytoplasmic sialidase
- low expression, mainly in skeletal muscle
- hydrolysis of GM₃; weak against GM₂ or GM₁
- induces proliferation and spontaneous differentiation of myoblast cells
- potential role in early steps of neuronal differentiation

- **Neu3**


- plasma membrane sialidase
- implicated in cell signaling and insulin signaling



- **Neu4**

- mitochondrial? lysosomal sialidase?
- implicated in apoptosis?

Seyrantepe et al., 2008



HUMAN NAs


- Human sialidases share a high sequence identity when comparing to the influenza virus neuraminidase

- Neu2 compared with:

- Neu1.....23 %
- Neu3.....38 %
- Neu4.....34 %
- influ NA...17 %

- Conserved residues for sialic acid coordination and enzymatic activity

... influenza virus



EFFECTS OF ANTI-FLU DRUGS IN HUMAN?

**WED., NOV.
15TH, 2006**

Tamiflu will carry caution on

Roche Laboratories inc.:

“...dose dependent increase in the incidence rates of a variety of minor skeletal abnormalities...”

GlaxoSmithKline:

“...increase in the incidence rates of a variety of minor skeleton alterations...”

...cases of delirium, hallucinations and other unusual psychiatric behavior in children treated with the drug. Most were Japanese children.

The Food and Drug Administration said a relationship between the drug and the behavior had not been established and that the

mal behavior flagged in the updated label.

The surprise change came three days before an FDA panel of outside experts was to discuss whether to recommend that the agency add the precautionary language to the Tamiflu label.

In documents

influenza drug Tamiflu and users' reported bizarre behavior. REUTERS PHOTO


of bird flu. The drug doesn't prevent flu but can reduce the length and severity of its symptoms.

Previously, Roche has cited studies from the United States and Canada


NEU2 SAMPLE PREPARATION

- Recombinant expression (GST-tagged protein)
- Protein purification (affinity, ion exchange chromatography)

- > monodisperse sample
- > highly pure and intact
- > ready for crystallization
- > active protein





activity test at different pH









PSX ROBOT



OBSERVATION SYSTEM



STRUCTURAL BIOLOGY

Identify a
target model


Target

X-ray
analysis

Detailed
analysis

structural biology

RESEARCH AND SUPPORT ACTIVITIES



• What are we doing?

RESEARCH AND SUPPORT ACTIVITIES

Starting year

Status

Synchrotron Ring

Injection

X-ray source

Wavelength (Å)

Energy resolution ($\Delta E / E$)

Photon flux (photons / sec, @ 1.0 Å)

Slit size for flux measurement (μm^2)

Detector

Type

Active area (mm^2)

Pixel size (μm^2)

Pixel number

Frame data size (MByte)

Readout time (sec)

Typical exposure time (sec / deg)

Data collection time per frame (sec)

**Typical data collection time (min, 180 frames)
(using the IEEE1394 interface)**

Camera distance (mm)

Detector vector offset (mm)

Sample changer

Software image processing

BL-1A	BL-5A	BL-17A	AR-NW12A	AR-NE3A
2010	2004	2006	2003	2009
Operational	Operational	Operational	Operational	Operational
	PF		PF AR	
	Top-up		Twice / day (8:30. 20:30)	
Short-gap undulator	Multipole wiggler	Short-gap undulator	Undulator	Undulator
0.9 - 1.1 / 2.7 - 3.0	0.7 - 1.9	0.9 - 2.1	0.7 - 1.9	0.7 - 1.9
2.5×10^{-4}	2.5×10^{-4}	2.5×10^{-4}	2.5×10^{-4}	2.5×10^{-4}
2×10^{10}	2×10^{11}	6.6×10^9	2.0×10^{11}	8.0×10^{11}
2×10^9 (@2.7 Å)		1.3×10^{10} (@2.0 Å)		
10 x 10	200 x 200	20 x 20	200 x 200	200 x 200
Quantum 270	Quantum 315r	Quantum 210r	Quantum 210r	Quantum 270
CCD	CCD	CCD	CCD	CCD
270 x 270	315 x 315	210 x 210	210 x 210	270 x 270
64.8 x 64.8	102 x 102	51 x 51	102 x 102	64.8 x 64.8
4168 x 4168	3072 x 3072	4096 x 4096	2048 x 2048	4168 x 4168
34	19	32	8.0×10^{11}	34
1.1	0.3	1	0.3	1.1
Exp. time + 2.7	Exp. time + 1.6	Exp. time + 2.7	Exp. time + 1.6	Exp. time + 2.7
11	14	24	14	11
6	6 (24)	6	6	6
40 - 500	60-950	40-700	60-950	60-500
0 - 100	0 - 150	0-100	0-100	0-150

PAM

HKL2000, Mosflm, XDS...

RESEARCH AND SUPPORT ACTIVITIES

Astellas Beamline : Pharmaceuticals Beamline



Starting year

Status

Synchrotron Ring

Injection

X-ray source

Wavelength (Å)

Energy resolution ($\Delta E / E$)

Photon flux (photons / sec, @ 1.0 Å)

Slit size for flux measurement (μm^2)

Detector

Type

Active area (mm^2)

Pixel size (μm^2)

Pixel number

Frame data size (MByte)

Readout time (sec)

Typical exposure time (sec / deg)

Data collection time per frame (sec)

Typical data collection time (min, 180 frames)

(using the IEEE1394 interface)

Camera distance (mm)

Detector vector offset (mm)

Sample changer

Software image processing

AR-NE3A

2009

Operational

PFAR

Twice / day

Undulator

0.7 - 1.9

2.5×10^{-4}

8.0×10^{11}

200 x 200

Quantum 270

CCD

270 x 270

64.8 x 64.8

4168 x 4168

34

1.1

Exp. time + 2.7

11



6

60-500

0-150


PAM

HKL2000 etc.



RESEARCH AND SUPPORT ACTIVITIES

Astellas Beamline : Pharmaceuticals Beamline



Starting year

Status

Synchrotron Ring

Injection

X-ray source

Wavelength (Å)

Energy resolution ($\Delta E / E$)

Photon flux (photons / sec, @ 1.0 Å)

Slit size for flux measurement (μm^2)

Detector

Type

Active area (mm^2)

Pixel size (μm^2)

Pixel number

Frame data size (MByte)

Readout time (sec)

Typical exposure time (sec / deg)

Data collection time per frame (sec)

**Typical data collection time (min, 180 frames)
(using the IEEE1394 interface)**

Camera distance (mm)

Detector vector offset (mm)

AR-NE3A

2009

Operational

PFAR

Twice / day

Undulator

0.7 - 1.9

2.5×10^{-4}

8.0×10^{11}

200 x 200

Quantum 270

CCD

270 x 270

64.8 x 64.8

4168 x 4168

34

1.1

Exp. time + 2.7

11


6

60-500

0-150

Sample changer




PAM



Robots to the rescue !

synchrotron science




PF AUTOMATED MOUNTING SYSTEM



Gemini
Double
Tongue

RESEARCH AND SUPPORT ACTIVITIES

Low Energy Beamline



Starting year

Status

Synchrotron Ring

Injection

X-ray source

Wavelength (Å)

Energy resolution ($\Delta E / E$)

Photon flux (photons / sec, @ 1.0 Å)

Slit size for flux measurement (μm^2)

Detector

Type

Active area (mm^2)

Pixel size (μm^2)

Pixel number

Frame data size (MByte)

Readout time (sec)

Typical exposure time (sec / deg)

Data collection time per frame (sec)

**Typical data collection time (min, 180 frames)
(using the IEEE1394 interface)**

Camera distance (mm)

Detector vector offset (mm)

Sample changer

Software image processing


BL-1A
2010
Operational
PF
Top-up
Short-gap undulator
0.9 - 1.1 / 2.7 - 3.0
2.5×10^{-4}
2×10^{10}
2×10^9 (@2.7 Å)
10×10
Quantum 270
CCD
270×270
64.8×64.8
4168×4168
34
1.1
Exp. time + 2.7
11
6
40 - 500
0 - 100
PAM
HKL2000 etc.

RESEARCH AND SUPPORT K/B Mirrors / ITIES



Photon density focused on the crystal
(better diffraction for small crystals)

Improved resolution of the diffraction spots
(low readout noise)

Ray trace calculation (E = 4.23 keV)
FWHM: 45 μ m (H) x 4 μ m (V)
5 x 10¹¹ photons/s (@10 x 10 μ m²)





Vertically defocused beam
FWHM: 45 μ m (H) x 45 μ m (V)




Goal :
to get @ 4 keV
10¹⁰ ph / sec / 10x10 μ m²



Short gap undulator



Monochromator



He Chamber




Energy (eV)

Monochromator

He Chamber

RESEARCH AND SUPPORT ACTIVITIES




Low Energy Beamline



BL-1A
2010
Operational
PF
Top-up
Short-gap undulator
0.9 - 1.1 / 2.7 - 3.0
 2.5×10^{-4}
 2×10^{10}
 2×10^9 (@2.7 Å)
10 × 10
Quantum 270
CCD
270 × 270
64.8 × 64.8
4168 × 4168
34
1.1
Exp. time + 2.7
11
6
40 - 500
0 - 100
PAM
HKL2000 etc.

RESEARCH AND SUPPORT ACTIVITIES

Low Energy Beamline



Starting year

Status

Synchrotron Ring

Injection

X-ray source

Wavelength (Å)

Energy resolution ($\Delta E / E$)

Photon flux (photons / sec, @ 1.0 Å)

Slit size for flux measurement (μm^2)

Detector

Type

Active area (mm^2)

Pixel size (μm^2)

Pixel number

Frame data size (MByte)

Readout time (sec)

Typical exposure time (sec / deg)

Data collection time per frame (sec)

**Typical data collection time (min, 180 frames)
(using the IEEE1394 interface)**

Camera distance (mm)

Detector vector offset (mm)

Sample changer

Software image processing

BL-1A

2010

Operational

PF

Top-up

Short-gap undulator

0.9 - 1.1 / 2.7 - 3.0

2.5×10^{-4}

2×10^{10}

2×10^9 (@2.7 Å)

10×10

Quantum 270

CCD

270×270

64.8×64.8

4168×4168

34

1.1

Exp. time + 2.7

11

6

40 - 500

0 - 100

PAM

HKL2000 etc.

STRUCTURAL BIOLOGY

Identify a
target model

Target

X-ray
analysis

Detailed
analysis

Data
analysis

structural biology

STRUCTURAL BIOLOGY

Identify a
target model

Target

X-ray
analysis


Structure
determination

Detailed
analysis

Data
analysis

structural biology




NEU2 INHIBITION BY NIs








DANA: $K_i = 0.060$ mM

zanamivir (Relenza):
 $K_i = 0.011$ mM

peramivir: $K_i = 0.563$ mM




Relenza




DANA

$K_i=0.060$ mM
H-bonds: 10



**zanamivir
(Relenza)**

$K_i=0.011$ mM
H-bonds: 13



**Active site
free form**

R304

Y334

R21

R237

L217

E39

Y181


N86

E111


Y179

peramivir

$K_i=0.563$ mM
H-bonds: 8




RESEARCH AND SUPPORT ACTIVITIES



• What are we doing?

UV FOR CENTERING & PHASING







near to middle UV
(200~400 nm / 3.10~6.20 eV)
react with:

cytosines
(DNA & RNA)

aromatics
(proteins)



Specific Highlighting of Biological Crystals (protein / DNA / RNA)

crystals in drops









crystal identification
in loops at
beamlines (UV-LED
based, no
noticeable damage
one samples)


Specific Radiation Damage on Biological Samples



HIGH-PRESSURE SET-UP




CONCLUSIONS




Identify a target model







X-ray analysis




Structure determination



Detailed analysis




Data analysis



ACKNOWLEDGMENTS



KEK - PF



TPRP

Targeted Proteins Research Program

MEXT



Naohiro Matsugaki

BL-1A & General questions
naohiro.matsugaki@kek.jp



Yusuke Yamada

BL-5A & AR-NE3A & RCM
yusuke.yamada@kek.jp



Masahiro Hiraki

Robots
masahiko.hiraki@kek.jp



Noriyuki Igarashi

BL-17A
noriyuki.igarashi@kek.jp



... and more than
40 different collaborations worldwide
(SACLA XFEL, SPring-8, AS...)

Leo Chavas

AR-NW12A

leonard.chavas@kek.jp

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200

**Substrate modeling
(Prof. Woods)**

**Human enzymes
(Dr. Monti)**

**Enzymatic mechanism
(Prof. Withers)**

**Space crystallization
(Dr. Satoh; JAXA)**

**Biotechnology
(Prof. Itoh
Tokushima Univ.)**

**Substrate mimic
(Prof. Sodeoka
RIKEN)**

**Inhibitor design
(Prof. von Itzstein)**

**Tamiflu-related
(Prof. McKimmBreschkin)**

**Influenza-related
(Prof. Colman)**